by April Breyer Menon | Jul 1, 2019
Venable partner Ha Kung Wong discusses the impact of product drift on biosimilars in an article for Pharm Manufacturing, including the opportunity for product drift concerns to be addressed by the FDA as part of its Biosimilar Action Plan. The article can be viewed...
by April Breyer Menon | Jun 26, 2019
Venable partner Ha Kung Wong spoke at ISPOR’s annual conference as part of a panel that discussed the biosimilar market in the US. As a follow-up to that presentation, Ha Kung participated in a Q&A for Biosimilar Development, including providing thoughts...
by April Breyer Menon | Jun 25, 2019
Venable partner Ha Kung Wong spoke at the ACI 10th Summit on Biosimilars as part of a panel that reviewed the economics of biosimilars and generic drugs. Highlights from his presentation comparing biosimilar markets in Europe and the United States and his take-home...
by April Breyer Menon | Jun 14, 2019
Venable partner Ha Kung Wong commented on the Terminating the Extension of Rights Misappropriated Act, or TERM Act, H.R. 3199, as part of the Law360 article “New Bill Would Reshape Drug Patent Cases in Uncertain Ways,” available here. The TERM Act was...
by April Breyer Menon | May 23, 2019
Venable partner Ha Kung Wong spoke at the ISPOR 2019 annual meeting as part of a panel that reviewed the current state of the biosimilar market and challenges to biosimilar uptake in the U.S. His comments on pending Congressional action relating to the Purple Book,...
by April Breyer Menon | Mar 27, 2019
Ha Kung Wong comments on what could happen if the Trump administration is successful in persuading the Fifth Circuit Court of Appeals to affirm a lower court ruling that the Affordable Care Act is invalid for the Center for Biosimilars. View Full Article at the Center...